Is cannabidiol a drug acting on unconventional targets to control drug-resistant epilepsy?

Epilepsia Open. 2020 Jan 17;5(1):36-49. doi: 10.1002/epi4.12376. eCollection 2020 Mar.


Cannabis has been considered as a therapeutic strategy to control intractable epilepsy. Several cannabis components, especially cannabidiol (CBD), induce antiseizure effects. However, additional information is necessary to identify the types of epilepsies that can be controlled by these components and the mechanisms involved in these effects. This review presents a summary of the discussion carried out during the 2nd Latin American Workshop on Neurobiology of Epilepsy entitled "Cannabinoid and epilepsy: myths and realities." This event was carried out during the 10th Latin American Epilepsy Congress in San José de Costa Rica (September 28, 2018). The review focuses to discuss the use of CBD as a new therapeutic strategy to control drug-resistant epilepsy. It also indicates the necessity to consider the evaluation of unconventional targets such as P-glycoprotein, to explain the effects of CBD in drug-resistant epilepsy.

Keywords: P‐glycoprotein; cannabidiol; cannabis; drug‐resistant epilepsy.

Publication types

  • Review